Allogene Therapeutics
ALLO
171 hedge funds and large institutions have $663M invested in Allogene Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 51 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
18% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 51
14% more capital invested
Capital invested by funds: $582M → $663M (+$80.5M)
9.91% more ownership
Funds ownership: 81.57% → 91.47% (+9.9%)
3% less funds holding
Funds holding: 176 → 171 (-5)
19% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 27
36% less call options, than puts
Call options by funds: $318K | Put options by funds: $495K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$127M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$16.9M |
| 3 |
JP Morgan Chase
New York
|
+$6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.12M |
| 5 |
PCIG
Partners Capital Investment Group
Boston,
Massachusetts
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$26.2M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$7.39M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.4M |
| 4 |
Millennium Management
New York
|
-$4.29M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.1M |
ALLO Hedge Fund Activity: Q2 2023 in Review
171 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2023, worth a combined $663M — up 14% from $582M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ALLO and 22 opened new positions — a net loss of 5 holders — while 51 trimmed existing stakes and 60 added.
The largest buyer was Fidelity Investments, adding an estimated $127M. The largest seller was Capital International Investors, exiting entirely with an estimated $26.2M sold.
- 171 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2023, down from 176 in Q1 2023.
- Funds reported $663M of Allogene Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
- 22 funds opened new Allogene Therapeutics positions in Q2 2023 and 27 closed out, a net change of -5 holders.
- The largest Allogene Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $127M added.
- The largest Allogene Therapeutics seller in Q2 2023 was Capital International Investors, an estimated $26.2M sold.
Based on aggregated 13F filings for Q2 2023.